Statement Of Cash Flows [Abstract]

Xspray Pharma - Filing #702829

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
- SEK
- SEK
- SEK
96 698 SEK
96 698 SEK
52 410 SEK
- SEK
52 410 SEK
- SEK
- SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for depreciation and amortisation expense
8 870 SEK
7 689 SEK
Adjustments for losses (gains) on disposal of non-current assets
98,000 SEK
113,000 SEK
Interest paid, classified as operating activities
4,000 SEK
8,000 SEK
Interest received, classified as operating activities
1 878 SEK
674,000 SEK
Cash flows from (used in) operating activities
51 607 SEK
47 792 SEK
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
- SEK
383,000 SEK
Purchase of property, plant and equipment, classified as investing activities
1 313 SEK
4 572 SEK
Cash flows from (used in) investing activities
105 818 SEK
96 828 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
99 877 SEK
249 320 SEK
Payments of lease liabilities, classified as financing activities
2 154 SEK
936,000 SEK
Cash flows from (used in) financing activities
103 708 SEK
260 345 SEK
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
53 717 SEK
115 726 SEK
Cash and cash equivalents
271 881 SEK
325 598 SEK
209 872 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.